

LA JOLLA PHARMACEUTICAL COMPANY

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Revenue				
Contract revenue - related party	\$ 647	\$ —	\$ 647	\$ —
Total revenue	647	—	647	—
Expenses				
Research and development	7,781	2,625	19,637	6,218
General and administrative	3,353	2,436	11,122	8,259
Total expenses	11,134	5,061	30,759	14,477
Loss from operations	(10,487)	(5,061)	(30,112)	(14,477)
Other income, net	13	9	33	13
Net loss and comprehensive loss	\$ (10,474)	\$ (5,052)	\$ (30,079)	\$ (14,464)
Basic and diluted net loss per share	\$ (0.70)	\$ (0.37)	\$ (1.99)	\$ (1.58)
Shares used in computing basic and diluted net loss per share	14,899	13,646	15,129	9,131

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Balance Sheets
(in thousands, except share and par value amounts)

	September 30, 2015	December 31, 2014
	(Unaudited)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 135,055	\$ 48,555
Restricted cash	237	37
Prepaid clinical expenses	360	1,528
Prepaid expenses and other current assets	484	137
Total current assets	136,136	50,257
Property and equipment, net	1,751	279
Other assets	57	—
Total assets	\$ 137,944	\$ 50,536
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 2,567	\$ 730
Accrued expenses	1,145	926
Accrued payroll and related expenses	629	424
Total current liabilities	4,341	2,080
Shareholders' equity:		
Common Stock, \$0.0001 par value; 100,000,000 shares authorized, 18,241,509 and 15,225,980 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	2	2
Series C-1 ² Convertible Preferred Stock, \$0.0001 par value; 11,000 shares authorized, 3,906 and 3,917 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	3,906	3,917
Series F Convertible Preferred Stock, \$0.0001 par value; 10,000 shares authorized, 2,737 and 2,798 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	2,737	2,798
Additional paid-in capital	643,651	528,353
Accumulated deficit	(516,693)	(486,614)
Total shareholders' equity	133,603	48,456
Total liabilities and shareholders' equity	\$ 137,944	\$ 50,536